Abeona Therapeutics Inc. announced on June 30, 2025, that it has been added as a member of the U.S. small-cap Russell 2000® Index and the broad-market Russell 3000® Index. This inclusion is part of the annual reconstitution of the Russell stock indexes and became effective at the open of U.S. equity markets on the same day. This event follows closely on the heels of ZEVASKYN™'s FDA approval.
Membership in these widely recognized indexes is significant as they are used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2024, approximately $10.6 trillion in assets are benchmarked against the Russell U.S. indexes. This inclusion is expected to amplify Abeona's positive momentum as it progresses with ZEVASKYN's commercial launch.
The addition to these indexes provides an opportunity for Abeona to engage with a broader audience of investors, potentially increasing liquidity and investor interest in the company's stock. Membership in the Russell 3000® Index also means automatic inclusion in either the large-cap Russell 1000® Index or small-cap Russell 2000® Index, as well as appropriate growth and value style indexes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.